Neuromod Devices · Neuromodulation · Marketed
MarketedDeviceTinnitus NeuromodulationStronger sources
Explore
Program Map
Start with a treatment, device, company, diagnosis, or trial ID. Each record keeps the source trail close to the claim.
161Main(26 active)
148Status checked
135Strong
320Backlog
More filters and sort (1 active)
19 records in Main database · 14 strong · 17 status checked
AudioCure Pharma · Small Molecule · Phase 2
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
91%
Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossTinnitus
Population
AdultSudden / SSNHLTinnitus
Auricle Inc. · Neuromodulation · Phase 2
ActiveDeviceTinnitus NeuromodulationStronger sources
Sound Pharmaceuticals · Small Molecule · Phase 3
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
90%
Indications
Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossTinnitus
Population
AdultNoise-InducedTinnitusCisplatin Ototoxicity
Neuromonics · Neuromodulation · Marketed
MarketedSoftware/NeurotechTinnitus NeuromodulationStronger sources
Evidence
regulatory
Confidence
88%
Indications
Tinnitus
Population
AdultTinnitusSound TherapyPersonalized Audio
Beltone · Hearing Aid/Software · Marketed
MarketedDevicePrescription Hearing AidsStronger sources
Evidence
company
Confidence
86%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing LossTinnitus
Population
AdultAge-RelatedPost-LingualTinnitus
Duearity · Neuromodulation · Marketed
MarketedDeviceTinnitus NeuromodulationStronger sources
Signia · Neuromodulation · Marketed
MarketedSoftware/NeurotechTinnitus NeuromodulationStronger sources
Evidence
company
Confidence
85%
Indications
TinnitusHearing Loss
Population
AdultTinnitusSound TherapyNotched Sound
ELEHEAR · Hearing Aid/Software · Marketed
MarketedDeviceOTC Hearing AidsStronger sources
Evidence
company
Confidence
84%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing LossTinnitus
Population
AdultAge-RelatedMild to ModeratePost-Lingual
Oticon · Neuromodulation · Marketed
MarketedSoftware/NeurotechTinnitus NeuromodulationStronger sources
Evidence
company
Confidence
84%
Indications
TinnitusHearing Loss
Population
AdultTinnitusSound TherapyHearing Aid Feature
ReSound · Neuromodulation · Marketed
MarketedSoftware/NeurotechTinnitus NeuromodulationStronger sources
Evidence
company
Confidence
84%
Indications
TinnitusHearing Loss
Population
AdultTinnitusSound TherapyMobile App
Starkey · Neuromodulation · Marketed
MarketedSoftware/NeurotechTinnitus NeuromodulationStronger sources
Evidence
company
Confidence
84%
Indications
TinnitusHearing Loss
Population
AdultTinnitusSound TherapyHearing Aid Feature
Widex · Neuromodulation · Marketed
MarketedSoftware/NeurotechTinnitus NeuromodulationStronger sources
Evidence
company
Confidence
84%
Indications
TinnitusHearing Loss
Population
AdultTinnitusSound TherapyHearing Aid Feature
Phonak · Neuromodulation · Marketed
MarketedSoftware/NeurotechTinnitus NeuromodulationStronger sources
Evidence
company
Confidence
82%
Indications
TinnitusHearing Loss
Population
AdultTinnitusSound TherapyHearing Aid Feature
Otonomy · Small Molecule · Phase 2
DiscontinuedTherapeutic
Altamira Therapeutics · Small Molecule · Phase 3
DiscontinuedTherapeutic
Otologic Pharmaceutics · Small Molecule · Phase 1
CompletedTherapeutic
Evidence
company
Confidence
89%
Indications
Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossTinnitus
Population
AdultNoise-InducedTinnitus
Lunan Better Pharmaceutical Co., Ltd. · Small Molecule · Phase 2/3
ActiveTherapeutic
Evidence
trial
Confidence
88%
Indications
Hearing LossTinnitus
Population
AdultUnilateralMeniere Disease
Merz Pharmaceuticals GmbH · Small Molecule · Phase 3
CompletedTherapeutic